AKT1 and non-small cell lung carcinoma: Interestingly, prior analyses of non-transformed EGFR-mutant NSCLC have demonstrated significantly lower rates of PIK3CA/AKT/PTEN when compared to this cohort (14.9% vs. 73%, respectively) [25].